Last reviewed · How we verify
NCT05393596
Effects of Virtual Reality Software on Levels of Stigma Towards People With Mental Illness.
NA trial testing Virtual Reality Software Intervention in Social Stigma in 122 participants. Completed in 1 December 2022.
1 December 2022
Quick facts
| Lead sponsor | Universidad del Desarrollo |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 122 |
| Start date | 1 June 2022 |
| Primary completion | 1 December 2022 |
| Estimated completion | 1 December 2022 |
| Sites | 1 location across Chile |
Drugs / interventions tested
- Virtual Reality Software Intervention
Conditions studied
- Social Stigma — all drugs for Social Stigma →
- Virtual Reality — all drugs for Virtual Reality →
Sponsor
Universidad del Desarrollo — full company profile →
Who can join
18 and older, any sex, with Social Stigma or Virtual Reality. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the research is to contribute to the reduction of stigma among university students among people with serious psychiatric illnesses and to improve future educational processes focused on the social inclusion of people with these mental health problems. For this purpose, the methodology proposed is a mixed (qualitative and quantitative), with an experimental design. Students of the Universidad del Desarrollo will be contacted and invited to participate voluntarily, after signing an informed consent of the research. This procedure will consist of the use of a virtual reality software in the university premises, together with the application of a survey with scales validated in Chile before and after the intervention, in addition to a semi-structured interview about the experience in the use of the software, together with the identification of strengths and opportunities for improvement of the intervention. The total estimated duration of the procedure is approximately 35 minutes. It is expected to determine the level of stigma towards mental illness before and after the development of the virtual reality intervention, in addition to describing the perception of the students' experience after participating in the intervention (including an analysis of strengths and opportunities for improvement). The general objective of the present research is to evaluate the effect of a virtual reality intervention on levels of stigma towards people with mental illness in university students.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Reducing Stigma Toward People with Serious Mental Illness Through a Virtual Reality Intervention: A Randomized Controlled Trial.
Rodríguez-Rivas ME, Cangas AJ, Martin A, Romo J, et al · · 2024 · cited 11× · PMID 37695822 · DOI 10.1089/g4h.2023.0118
Verify or expand the search:
- PubMed search for NCT05393596
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Social Stigma
Currently open trials in the same condition.
- NCT06440785 — Taylor Swift and Mental Health Outcomes · recruiting
- NCT05505227 — Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing · NA · active not recruiting
Other Universidad del Desarrollo trials
Trials by the same sponsor.
- NCT06260111 — Photobiomodulation for Oral Mucositis and Functional Impairments During Hematopoietic Stem Cell Transplantation · NA · recruiting
- NCT05790837 — Workplace Intervention to Reduce Sitting Time: a Randomized Clinical Trial. · NA · completed
- NCT05291208 — Clinical Trial Through Combined tACS Therapy in Patients With Mild Cognitive Impairment · Phase 2 · unknown
- NCT05425069 — Evaluation of the EEG Connectivity Using Predominant Dexmedetomidine as Anesthetic in Fragile Brains · unknown
- NCT04992182 — Reactogenicity, Safety, and Immunogenicity of Covid-19 Vaccine Booster · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05393596 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidad del Desarrollo
- Last refreshed: 7 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05393596.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing